The Effects of PG102, a Water Soluble Extract From Actinidia Arguta, on Serum Total IgE Levels

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to evaluate the efficacy of PG102 at lowering levels of total IgE in asymptomatic subjects with atopy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of a Depigmented Extract of Phleum in Local Allergic Rhinitis

NCT02126111

Allergic Rhinitis

COMPLETED PHASE2

Phase 2 Study in Adults Sensitized to Short Ragweed

NCT00670384

Allergic Rhinitis

WITHDRAWN PHASE2

Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense

NCT00501527

Rhinitis, Allergic, Seasonal Conjunctivitis, Allergic Asthma

COMPLETED PHASE2

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen

NCT00916422

Seasonal Allergic Rhinitis

COMPLETED PHASE3

Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge

NCT01657097

Allergic Rhinitis Asthma

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asymptomatic Subjects With Atopy and Elevated Serum IgE

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PG102 group

Group Type EXPERIMENTAL

PG102, a water soluble extract from Actinidia arguta

Intervention Type DIETARY_SUPPLEMENT

PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks

placebo group

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PG102, a water soluble extract from Actinidia arguta

PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks

Intervention Type DIETARY_SUPPLEMENT

placebo

placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* subjects who have atopy but no allergy-related symptoms
* subjects with total IgE levels of 300IU/ml or more
* acquisition of written informed consent prior to commencement of study
* no serious clinical symptoms and normal laboratory test results; in case of abnormal finding, subjects whose conditions are not deemed severe from the judgement of investigators

Exclusion Criteria

* individuals with normal levels of total serum IgE
* ue of one or more allergic drugs
* serious clinical conditions (such as malignancies, severe cardiovascular disease etc.)
* serious mental disorder
* pregnant woman or woman of childbearing potential within 3 months
* subjects who participated in other clinical trials in the past 6months
* individuals who have a plan to participate in another clinical trials during this trial
* subjects with a history of kiwi allergy
* subjects whose conditions are inappropriate by investigators

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes